COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response.
Anna ZabalzaSimón Cárdenas-RobledoPaula TaglianiGeorgina ArrambideSusana Otero-RomeroPere Carbonell-MirabentMarta Rodriguez-BarrancoBreogán Rodríguez-AcevedoJuan Luis Restrepo VeraMireia Resina-SallesLuciana MidagliaÁngela Vidal-JordanaJordi RíoIngrid GalanJoaquin CastilloÁlvaro Cobo-CalvoManuel Comabella LopezCarlos NosJaume Sastre-GarrigaMar TintoreXavier MontalbanPublished in: European journal of neurology (2021)
Multiple sclerosis patients present similar incidence, risk factors and outcomes for COVID-19 as the general population. Patients treated with an anti-CD20 therapy for a longer period of time might be at a higher risk of COVID-19 and less than 20% generate an antibody response. Only age was related to severity.